<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043912</url>
  </required_header>
  <id_info>
    <org_study_id>EV002</org_study_id>
    <nct_id>NCT02043912</nct_id>
  </id_info>
  <brief_title>Drug Interactions With Risk of QT-prolongation in a General Hospital</brief_title>
  <official_title>Drug Interactions With Risk of QT-prolongation in a General Hospital: an Epidemiological Point Prevalence Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this epidemiological point prevalence study, medication profiles of patients with
      haloperidol treatment will be checked for drug interactions with risk of QT-prolongation.
      Additional clinical risk factors for developing QT-prolongation and safety measurements will
      be documented.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: epidemiological point prevalence study

      Target population: Patients with haloperidol treatment

      The following aspects will be investigated:

        -  The medication profiles will be checked for drug interactions with risk of
           QT-prolongation.

        -  Clinical risk factors for developing QT-prolongation (gender, age, (history of)
           cardiovascular disease, comorbidity,...) and lab results will be collected.

        -  Safety measurements (e.g. ECG) will be documented.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>QTc-interval (corrected for heart rate)</measure>
    <time_frame>maximum one year before inclusion / one week after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of drug interactions (with risk of QT-prolongation)</measure>
    <time_frame>one week before/after inclusion</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>number of patients with an ECG before or after the start of haloperidol</measure>
    <time_frame>maximum one year before inclusion / one week after inclusion</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">222</enrollment>
  <condition>QT-prolongation</condition>
  <arm_group>
    <arm_group_label>patients treated with haloperidol</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <arm_group_label>patients treated with haloperidol</arm_group_label>
    <other_name>Haldol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who are treated with haloperidol (every tuesday we will make a selection of the
        patients who received haloperidol on monday)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  treatment with haloperidol (started in the hospital)

        Exclusion Criteria:

          -  age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eline Vandael, PhD-student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Katholieke Universiteit Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>June 10, 2014</last_update_submitted>
  <last_update_submitted_qc>June 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Eline Vandael</investigator_full_name>
    <investigator_title>PhD-student</investigator_title>
  </responsible_party>
  <keyword>QT-prolongation</keyword>
  <keyword>Torsade de Pointes</keyword>
  <keyword>Haloperidol</keyword>
  <keyword>Drug interactions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Long QT Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

